TY - JOUR
T1 - Expression of the phosphoinositide 3-kinase p110δ isoform and its clinicopathological significance in gastric cancer
AU - Ji, Byounghoon
AU - Lee, Hyoun Wook
AU - Lee, Eun Hee
AU - Park, Moon Il
AU - Kim, Mee Seon
AU - Kim, Kyungeun
AU - Roh, Mee Sook
AU - Kim, Seok Hyun
AU - Ji, Jun Ho
AU - Kim, Kwang Min
AU - Oh, Jieun
AU - Kim, Yong Seok
AU - Choi, Seong Hee
PY - 2016
Y1 - 2016
N2 - Protein p110δ is an isoform of the catalytic subunit of class I phosphoinositide 3-kinases (PI3Ks). PI3Ks are involved in the regulation of cell survival, growth, proliferation, and migration, and have been implicated in the oncogenesis of hematologic malignancies. In this study, we evaluated the expression of p110δ in gastric cancer (GC) and its association with various clinicopathological factors and patient survival. One hundred seventy-four GC cases, included in our previous tissue microarray blocks, were immunohistochemically stained for p110δ. Of the 174 tumors, 158 (90.8%) were positive for p110δ. The rate of p110δ positive GCs was significantly higher in those with diffuse type (P=0.018), larger tumor size (P=0.002), lymphovascular invasion (P=0.012), and advanced pT (P < 0.001), pN (P < 0.001), and TNM stages (P < 0.001). In addition, the p110δ-positive group had poorer overall survival (P=0.002) and recurrence-free survival (P=0.075) than that of the negative group. However, multivariate analysis showed that p110δ was not an independent prognostic factor. Our results suggest that p110δ can play an important role in GC oncogenesis and is a promising therapeutic target in GC. Additional studies on the use of p110δ-specific inhibitors, and the possibility of p110δ immunostaining as a prognostic or predictive biomarker in solid cancers, including GC, are recommended.
AB - Protein p110δ is an isoform of the catalytic subunit of class I phosphoinositide 3-kinases (PI3Ks). PI3Ks are involved in the regulation of cell survival, growth, proliferation, and migration, and have been implicated in the oncogenesis of hematologic malignancies. In this study, we evaluated the expression of p110δ in gastric cancer (GC) and its association with various clinicopathological factors and patient survival. One hundred seventy-four GC cases, included in our previous tissue microarray blocks, were immunohistochemically stained for p110δ. Of the 174 tumors, 158 (90.8%) were positive for p110δ. The rate of p110δ positive GCs was significantly higher in those with diffuse type (P=0.018), larger tumor size (P=0.002), lymphovascular invasion (P=0.012), and advanced pT (P < 0.001), pN (P < 0.001), and TNM stages (P < 0.001). In addition, the p110δ-positive group had poorer overall survival (P=0.002) and recurrence-free survival (P=0.075) than that of the negative group. However, multivariate analysis showed that p110δ was not an independent prognostic factor. Our results suggest that p110δ can play an important role in GC oncogenesis and is a promising therapeutic target in GC. Additional studies on the use of p110δ-specific inhibitors, and the possibility of p110δ immunostaining as a prognostic or predictive biomarker in solid cancers, including GC, are recommended.
KW - Gastric cancer
KW - Immunohistochemistry
KW - P110δ
KW - PI3K
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84994259609&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84994259609
SN - 1936-2625
VL - 9
SP - 9415
EP - 9421
JO - International Journal of Clinical and Experimental Pathology
JF - International Journal of Clinical and Experimental Pathology
IS - 9
ER -
